바이오엠엑스(PHGE) is a Industrials sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
| Index | - | P/E | - | EPS (ttm) | -24.96 | Insider Own | 23.48% | Shs Outstand | 11.8M | Perf Week | -1.3% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -37.33% | Shs Float | 9.0M | Perf Month | -50.03% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 1.54% | Short Float | 2.11% | Perf Quarter | -82.22% |
| Income | -0.05B | P/S | - | EPS this Y | - | Inst Trans | -0.47% | Short Ratio | 0.02 | Perf Half Y | -95.08% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -182.66% | Short Interest | 0.19M | Perf YTD | -89.44% |
| Book/sh | -2.48 | P/C | 1.99 | EPS past 3/5Y | 50.25% 38.28% | ROE | -354.26% | 52W High | -98.56% ($13.70) | Perf Year | -97.58% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -1971.06% | 52W Low | 11.53% ($0.18) | Perf 3Y | -99.75% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -92.2% | Gross Margin | - | Volatility(W/M) | 8.03% 10.74% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.24 | EPS Q/Q | -17.22% | Profit Margin | - | RSI (14) | 27.55 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.24 | Sales Q/Q | - | SMA20 | -20.93% ($0.25) | Beta | 1.38 | Target Price | $399 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/04/01 | SMA50 | -63.5% ($0.55) | Rel Volume | 0.1 | Prev Close | $0.19 |
| Employees | 20 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 1.69% - | SMA200 | -94.69% ($3.77) | Avg Volume(3M) | 8.04M | Price | $0.2 |
| IPO | 2019/3/13 | Option/Short | No/Yes | Trades | 569 | Volume | 804,495 | Change | 4.44% |
BiomX Inc (PHGE) Investment Analysis
What kind of company is BiomX Inc?
🧬 BiomX (ticker not specified) is a clinical-stage biotech developing precision antibacterial therapies based on natural and genetically engineered bacteriophages. BX211, for diabetic foot osteomyelitis (DFO), demonstrated a meaningful reduction in ulcer size compared with placebo in a Phase 2 trial, while BX004, targeting chronic Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients, is currently in a Phase 2b clinical trial. The company's approach is distinguished by addressing the key weaknesses of conventional antibiotics—namely, antibiotic resistance and biofilm formation.
Learn more about BiomX Inc →Key Events
Is it profitable?
What's the outlook?
Did earnings meet expectations?
Is it growing?
Has the stock risen over the long term?
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current price $0.20 below the midline ($0.25). Normal downward flow. Below the Ichimoku cloud (bearish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
MACD -0.109 · Signal -0.130 · Hist 0.021. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
RSI 27.6 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 20.0.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Key metrics such as PER and PBR are unavailable, so valuation is omitted.
Who owns it?
How much does it pay in dividends?
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| PHGE This Stock | $2.3M | - | - | -354.26% ▼ | - | +4.4% |
SPCX | $1.51T | - | 43.0 ▼ | - | - | -1.2% |
CAT | $402.3B | 43.5 ▼ | 21.6 ▼ | 51.35% ▲ | 0.71% ▼ | -1.7% |
GE | $375.2B | 42.6 ▼ | 21.3 ▼ | 48.75% ▲ | 0.5% ▼ | +2.2% |
RTX | $294.4B | 38.5 ▼ | 4.4 ▼ | 12.02% ▲ | 1.3% ▲ | +2.6% |
GEV | $265.4B | 28.5 ▼ | 22.2 ▼ | 91.48% ▲ | 0.19% ▼ | -1.8% |
| Sector Avg | - | 27.8 | 2.7 | 6.31% | 1.25% | - |
FAQ
What kind of company is 바이오엠엑스(PHGE)?
바이오엠엑스(PHGE) belongs to the Industrials sector and operates in the Aerospace & Defense industry.
What is the market cap of PHGE?
The market cap of PHGE is approximately $2M, ranking 5,797 within its sector.
What is the 52-week high and low for PHGE?
PHGE has recorded a 52-week high of $13.70 and a low of $0.18.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.